adalimumab [Adalimumab]

tematický
357
Termíny

Humira

 

Adalimumab-adbm
Adalimumab-atto
Amjevita
Cyltezo
D2E7 Antibody
Humira

Perzistentní odkaz   https://www.medvik.cz/link/D000068879
Definice

Lék používaný při některých revmatických chorobách (revmatoidní, psoriatické artritidě, těžké Bechtěrevově nemoci). Monoklonální protilátka, imunosupresivum. (cit. Velký lékařský slovník online, 2017 http://lekarske.slovniky.cz)

A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.

DUI
D000068879 MeSH Prohlížeč
CUI
M0422769
Historická pozn.
2016 (2002)
Veřejná pozn.
2016; ADALIMUMAB was indexed under ANTIBODIES, MONOCLONAL, HUMANIZED 2002-2015

Povolená podhesla

AN
analýza 1
AD
aplikace a dávkování 99
BI
biosyntéza 1
CH
chemie 1
HI
dějiny
EC
ekonomika 5
PK
farmakokinetika 7
PD
farmakologie 62
PH
fyziologie
GE
genetika
IM
imunologie 3
IP
izolace a purifikace
CL
klasifikace 2
BL
krev 2
ME
metabolismus 1
UR
moč
CF
mozkomíšní mok
PO
otrava
AE
škodlivé účinky 60
TU
terapeutické užití 193
TO
toxicita
DE
účinky léků
RE
účinky záření
UL
ultrastruktura 1

D Chemikálie a léčiva
D12 aminokyseliny, peptidy a proteiny 16
D12.776 proteiny 2 587
D12.776.124 krevní proteiny 911
D12.776.124.486 imunoproteiny 14
D12.776.124.486.485 imunoglobuliny 1 494
D12.776.124.486.485.114 protilátky 1 818
D12.776.124.486.485.114.224 monoklonální protilátky 4 704
D12.776.124.486.485.114.224.060 humanizované monoklonální protilátky 2 960
D12.776.124.486.485.114.224.060.125 abciximab 14
D12.776.124.486.485.114.224.060.250 adalimumab 357
D12.776.124.486.485.114.224.060.313 alemtuzumab 125
D12.776.124.486.485.114.224.060.344 basiliximab 2
D12.776.124.486.485.114.224.060.375 bevacizumab 456
D12.776.124.486.485.114.224.060.438 brentuximab vedotin 45
D12.776.124.486.485.114.224.060.500 certolizumab pegol 49
D12.776.124.486.485.114.224.060.750 cetuximab 186
D12.776.124.486.485.114.224.060.766 daklizumab 6
D12.776.124.486.485.114.224.060.782 denosumab 158
D12.776.124.486.485.114.224.060.790 gemtuzumab 19
D12.776.124.486.485.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.486.485.114.224.060.798 ipilimumab 267
D12.776.124.486.485.114.224.060.813 natalizumab 158
D12.776.124.486.485.114.224.060.829 nivolumab 461
D12.776.124.486.485.114.224.060.844 omalizumab 115
D12.776.124.486.485.114.224.060.860 palivizumab 13
D12.776.124.486.485.114.224.060.864 panitumumab 62
D12.776.124.486.485.114.224.060.866 ramucirumab 1
D12.776.124.486.485.114.224.060.868 ranibizumab 63
D12.776.124.486.485.114.224.060.875 trastuzumab 278
D12.776.124.486.485.114.224.060.937 ustekinumab 125
D12.776.124.790 sérové globuliny 61
D12.776.124.790.651 imunoglobuliny 1 494
D12.776.124.790.651.114 protilátky 1 818
D12.776.124.790.651.114.224 monoklonální protilátky 4 704
D12.776.124.790.651.114.224.060 humanizované monoklonální protilátky 2 960
D12.776.124.790.651.114.224.060.125 abciximab 14
D12.776.124.790.651.114.224.060.250 adalimumab 357
D12.776.124.790.651.114.224.060.375 alemtuzumab 125
D12.776.124.790.651.114.224.060.407 basiliximab 2
D12.776.124.790.651.114.224.060.438 bevacizumab 456
D12.776.124.790.651.114.224.060.469 brentuximab vedotin 45
D12.776.124.790.651.114.224.060.500 certolizumab pegol 49
D12.776.124.790.651.114.224.060.750 cetuximab 186
D12.776.124.790.651.114.224.060.766 daklizumab 6
D12.776.124.790.651.114.224.060.782 denosumab 158
D12.776.124.790.651.114.224.060.790 gemtuzumab 19
D12.776.124.790.651.114.224.060.794 inotuzumab ozogamicin 12
D12.776.124.790.651.114.224.060.798 ipilimumab 267
D12.776.124.790.651.114.224.060.813 natalizumab 158
D12.776.124.790.651.114.224.060.829 nivolumab 461
D12.776.124.790.651.114.224.060.844 omalizumab 115
D12.776.124.790.651.114.224.060.860 palivizumab 13
D12.776.124.790.651.114.224.060.864 panitumumab 62
D12.776.124.790.651.114.224.060.866 ramucirumab 1
D12.776.124.790.651.114.224.060.868 ranibizumab 63
D12.776.124.790.651.114.224.060.875 trastuzumab 278
D12.776.124.790.651.114.224.060.937 ustekinumab 125
D12.776.377 globuliny 68
D12.776.377.715 sérové globuliny 61
D12.776.377.715.548 imunoglobuliny 1 494
D12.776.377.715.548.114 protilátky 1 818
D12.776.377.715.548.114.224 monoklonální protilátky 4 704
D12.776.377.715.548.114.224.200 humanizované monoklonální protilátky 2 960
D12.776.377.715.548.114.224.200.125 abciximab 14
D12.776.377.715.548.114.224.200.250 adalimumab 357
D12.776.377.715.548.114.224.200.375 alemtuzumab 125
D12.776.377.715.548.114.224.200.407 basiliximab 2
D12.776.377.715.548.114.224.200.438 bevacizumab 456
D12.776.377.715.548.114.224.200.469 brentuximab vedotin 45
D12.776.377.715.548.114.224.200.500 certolizumab pegol 49
D12.776.377.715.548.114.224.200.750 cetuximab 186
D12.776.377.715.548.114.224.200.766 daklizumab 6
D12.776.377.715.548.114.224.200.782 denosumab 158
D12.776.377.715.548.114.224.200.790 gemtuzumab 19
D12.776.377.715.548.114.224.200.794 inotuzumab ozogamicin 12
D12.776.377.715.548.114.224.200.798 ipilimumab 267
D12.776.377.715.548.114.224.200.813 natalizumab 158
D12.776.377.715.548.114.224.200.829 nivolumab 461
D12.776.377.715.548.114.224.200.844 omalizumab 115
D12.776.377.715.548.114.224.200.860 palivizumab 13
D12.776.377.715.548.114.224.200.864 panitumumab 62
D12.776.377.715.548.114.224.200.866 ramucirumab 1
D12.776.377.715.548.114.224.200.868 ranibizumab 63
D12.776.377.715.548.114.224.200.875 trastuzumab 278
D12.776.377.715.548.114.224.200.937 ustekinumab 125

ABP 501 Chemical MeSH Prohlížeč

BI 695501 Chemical MeSH Prohlížeč

FKB327 Chemical MeSH Prohlížeč

GP2017 Chemical MeSH Prohlížeč

PF-06410293 Chemical MeSH Prohlížeč

adalimumab biosimilar HS016 Chemical MeSH Prohlížeč

Přidat